Talis Biomedical Corp TLIS
We take great care to ensure that the data presented and summarized in this overview for Talis Biomedical Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TLIS
Top Purchases
Top Sells
About TLIS
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Insider Transactions at TLIS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 06
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
25,000
+9.13%
|
$25,000
$1.48 P/Share
|
|
Sep 05
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
5,100
+2.23%
|
$5,100
$1.4 P/Share
|
|
Sep 03
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
500
+0.23%
|
$2,000
$4.0 P/Share
|
|
Aug 30
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
151
+0.07%
|
$604
$4.25 P/Share
|
|
Aug 28
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
1,215
+0.55%
|
$3,645
$3.96 P/Share
|
|
Aug 26
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
13,167
+5.73%
|
$39,501
$3.9 P/Share
|
|
Nov 18
2021
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.7%
|
$200,000
$4.37 P/Share
|
|
Aug 13
2021
|
Ramesh Ramakrishnan |
SELL
Open market or private sale
|
Direct |
27,502
-41.59%
|
$192,514
$7.66 P/Share
|
|
Aug 13
2021
|
Ramesh Ramakrishnan |
BUY
Exercise of conversion of derivative security
|
Direct |
52,355
+27.43%
|
$52,355
$1.5 P/Share
|
|
May 17
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Direct |
11,000
+35.48%
|
$110,000
$10.11 P/Share
|
|
May 14
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Direct |
9,000
+50.0%
|
$90,000
$10.16 P/Share
|
|
Feb 17
2021
|
Brian Coe Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
30,931
+29.56%
|
-
|
|
Feb 17
2021
|
Karen E. Flick Chief of Staff, Sr. VP, Legal |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$32,000
$16.0 P/Share
|
|
Feb 17
2021
|
Douglas Liu Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$64,000
$16.0 P/Share
|
|
Feb 17
2021
|
John Roger Moody Jr Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+50.0%
|
$27,200
$16.0 P/Share
|
|
Feb 17
2021
|
Matthew L. Posard Director |
BUY
Open market or private purchase
|
Direct |
62,500
+50.0%
|
$1,000,000
$16.0 P/Share
|
|
Feb 17
2021
|
Ramesh Ramakrishnan |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$16,000
$16.0 P/Share
|
|
Feb 17
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Indirect |
312,500
+50.0%
|
$5,000,000
$16.0 P/Share
|
|
Feb 17
2021
|
Randal W. Scott Director |
BUY
Conversion of derivative security
|
Indirect |
1,390,064
+30.47%
|
-
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Conversion of derivative security
|
Indirect |
391,815
+44.36%
|
-
|